KR20230088337A - Glp-1/gip 이중 작용제 - Google Patents
Glp-1/gip 이중 작용제 Download PDFInfo
- Publication number
- KR20230088337A KR20230088337A KR1020237006545A KR20237006545A KR20230088337A KR 20230088337 A KR20230088337 A KR 20230088337A KR 1020237006545 A KR1020237006545 A KR 1020237006545A KR 20237006545 A KR20237006545 A KR 20237006545A KR 20230088337 A KR20230088337 A KR 20230088337A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- polypeptide
- lys
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Data Mining & Analysis (AREA)
- Software Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Artificial Intelligence (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021045240 | 2020-10-17 | ||
| IN202021045240 | 2020-10-17 | ||
| IN202121002837 | 2021-01-20 | ||
| IN202121002837 | 2021-01-20 | ||
| PCT/IB2021/059420 WO2022079639A1 (en) | 2020-10-17 | 2021-10-13 | Glp-1/gip dual agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230088337A true KR20230088337A (ko) | 2023-06-19 |
Family
ID=78302859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237006545A Pending KR20230088337A (ko) | 2020-10-17 | 2021-10-13 | Glp-1/gip 이중 작용제 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20240020543A1 (https=) |
| EP (1) | EP4204440A1 (https=) |
| JP (1) | JP7830441B2 (https=) |
| KR (1) | KR20230088337A (https=) |
| CN (1) | CN116171164A (https=) |
| AU (1) | AU2021361263A1 (https=) |
| BR (1) | BR112023003668A2 (https=) |
| CA (1) | CA3195155A1 (https=) |
| CL (1) | CL2023000960A1 (https=) |
| CO (1) | CO2023001960A2 (https=) |
| IL (1) | IL301109A (https=) |
| JO (1) | JOP20230077A1 (https=) |
| MX (1) | MX2023002906A (https=) |
| PE (1) | PE20231309A1 (https=) |
| TW (1) | TW202229323A (https=) |
| WO (1) | WO2022079639A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| US12281149B2 (en) | 2021-05-13 | 2025-04-22 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| EP4556487A1 (en) * | 2022-07-13 | 2025-05-21 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
| WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
| WO2024098718A1 (zh) * | 2022-11-07 | 2024-05-16 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
| CN115651075B (zh) * | 2022-12-12 | 2023-04-11 | 杭州信海医药科技有限公司 | 一种Tirzepatide的合成方法 |
| CN120865433A (zh) * | 2022-12-21 | 2025-10-31 | 勃林格殷格翰国际有限公司 | Glp1/gip/npy2受体的三重激动剂 |
| JP2025530024A (ja) * | 2023-01-18 | 2025-09-10 | シャンハイ ミンウェイ バイオテクノロジー カンパニー，リミテッド | 三重活性を有する融合タンパク質およびその応用 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| TW202500575A (zh) * | 2023-05-21 | 2025-01-01 | 美商卡默療法股份有限公司 | 具有或不具有體重相關合併症之過重或肥胖成人之治療 |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025163615A1 (en) | 2024-01-31 | 2025-08-07 | Sun Pharmaceutical Industries Ltd. | High level production of glp1 analogues |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007224019A1 (en) | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
| IN2014MN02304A (https=) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TWI582109B (zh) | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| MX2020010505A (es) * | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CN119499352A (zh) | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| KR20240051304A (ko) | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| TW202216746A (zh) * | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
-
2021
- 2021-10-13 PE PE2023000804A patent/PE20231309A1/es unknown
- 2021-10-13 AU AU2021361263A patent/AU2021361263A1/en active Pending
- 2021-10-13 EP EP21795004.7A patent/EP4204440A1/en active Pending
- 2021-10-13 WO PCT/IB2021/059420 patent/WO2022079639A1/en not_active Ceased
- 2021-10-13 US US18/249,055 patent/US20240020543A1/en active Pending
- 2021-10-13 JP JP2023519770A patent/JP7830441B2/ja active Active
- 2021-10-13 CN CN202180051573.5A patent/CN116171164A/zh active Pending
- 2021-10-13 MX MX2023002906A patent/MX2023002906A/es unknown
- 2021-10-13 CA CA3195155A patent/CA3195155A1/en active Pending
- 2021-10-13 IL IL301109A patent/IL301109A/en unknown
- 2021-10-13 TW TW110137941A patent/TW202229323A/zh unknown
- 2021-10-13 BR BR112023003668A patent/BR112023003668A2/pt unknown
- 2021-10-13 KR KR1020237006545A patent/KR20230088337A/ko active Pending
-
2023
- 2023-02-22 CO CONC2023/0001960A patent/CO2023001960A2/es unknown
- 2023-03-31 CL CL2023000960A patent/CL2023000960A1/es unknown
- 2023-04-16 JO JOJO/P/2023/0077A patent/JOP20230077A1/ar unknown
-
2024
- 2024-08-22 US US18/812,797 patent/US20240400613A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022079639A1 (en) | 2022-04-21 |
| JP7830441B2 (ja) | 2026-03-16 |
| JOP20230077A1 (ar) | 2023-04-16 |
| CL2023000960A1 (es) | 2023-11-10 |
| EP4204440A1 (en) | 2023-07-05 |
| US20240020543A1 (en) | 2024-01-18 |
| PE20231309A1 (es) | 2023-08-24 |
| US20240400613A1 (en) | 2024-12-05 |
| JP2023545662A (ja) | 2023-10-31 |
| CN116171164A (zh) | 2023-05-26 |
| CA3195155A1 (en) | 2022-04-21 |
| TW202229323A (zh) | 2022-08-01 |
| AU2021361263A1 (en) | 2023-02-16 |
| CO2023001960A2 (es) | 2023-05-08 |
| IL301109A (en) | 2023-05-01 |
| MX2023002906A (es) | 2023-04-05 |
| BR112023003668A2 (pt) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230088337A (ko) | Glp-1/gip 이중 작용제 | |
| JP7849310B2 (ja) | 長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト | |
| KR102801994B1 (ko) | 신규한 glp-1 유사체 | |
| EP2851429B1 (en) | Protein and protein conjugate for diabetes treatment, and applications thereof | |
| KR20110126589A (ko) | 글루카곤 유사체 | |
| KR20110126591A (ko) | 글루카곤 유사체 | |
| KR20110126592A (ko) | 글루카곤 유사체 | |
| EP1704165A1 (en) | Novel glp-1 compounds | |
| US11572399B2 (en) | Long-acting GIP peptide analogues | |
| CN111349155A (zh) | 一种胰高血糖素类似物及其制备方法和用途 | |
| CN115461360B (zh) | 持续型glp-1以及胰高血糖素受体双重激动剂 | |
| WO2022007805A1 (zh) | 新型多肽及其治疗用途 | |
| FI105013B (fi) | Menetelmä terapeuttisesti käyttökelpoisten CRF-analogien valmistamiseksi | |
| EA053025B1 (ru) | Двойные агонисты glp-1/gip | |
| CN115819619B (zh) | 一类glp-1/y2受体双重激动剂及其应用 | |
| KR20260022948A (ko) | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 | |
| CN119488582A (zh) | 一种glp-1和pyy孪药及其制备方法和应用 | |
| JP2012513981A (ja) | Ｇｌｐ−１アナログおよびその使用 | |
| JP2002293799A (ja) | 新規ペプチド及びそれを含有する消化管運動抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230223 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241011 Comment text: Request for Examination of Application |